The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Sohel Somani - One of the best experts on this subject based on the ideXlab platform.
-
long term outcomes in half dose verteporfin photodynamic therapy for chronic Central Serous Retinopathy
Clinical Ophthalmology, 2017Co-Authors: Nadeem Ali Dhirani, Yelin Yang, Sohel SomaniAbstract:Objective To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic Central Serous Retinopathy (CSR). Design Retrospective case series. Participants 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration. Methods Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6-8 week visit following the treatment, and final follow-up ranged from 5 to 70 months. Results The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (p<0.05). Central retinal thickness and choroidal thickness also significantly decreased at last follow-up (p<0.05). Eight of 45 eyes (18%) demonstrated a recurrence of CSR following treatment within the follow-up period. At the final follow-up, 41 out of the 45 eyes (91%) had complete resolution of subretinal fluid accumulation. Conclusion Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result.
Nadeem Ali Dhirani - One of the best experts on this subject based on the ideXlab platform.
-
long term outcomes in half dose verteporfin photodynamic therapy for chronic Central Serous Retinopathy
Clinical Ophthalmology, 2017Co-Authors: Nadeem Ali Dhirani, Yelin Yang, Sohel SomaniAbstract:Objective To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic Central Serous Retinopathy (CSR). Design Retrospective case series. Participants 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration. Methods Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6-8 week visit following the treatment, and final follow-up ranged from 5 to 70 months. Results The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (p<0.05). Central retinal thickness and choroidal thickness also significantly decreased at last follow-up (p<0.05). Eight of 45 eyes (18%) demonstrated a recurrence of CSR following treatment within the follow-up period. At the final follow-up, 41 out of the 45 eyes (91%) had complete resolution of subretinal fluid accumulation. Conclusion Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result.
Yelin Yang - One of the best experts on this subject based on the ideXlab platform.
-
long term outcomes in half dose verteporfin photodynamic therapy for chronic Central Serous Retinopathy
Clinical Ophthalmology, 2017Co-Authors: Nadeem Ali Dhirani, Yelin Yang, Sohel SomaniAbstract:Objective To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic Central Serous Retinopathy (CSR). Design Retrospective case series. Participants 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration. Methods Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6-8 week visit following the treatment, and final follow-up ranged from 5 to 70 months. Results The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (p<0.05). Central retinal thickness and choroidal thickness also significantly decreased at last follow-up (p<0.05). Eight of 45 eyes (18%) demonstrated a recurrence of CSR following treatment within the follow-up period. At the final follow-up, 41 out of the 45 eyes (91%) had complete resolution of subretinal fluid accumulation. Conclusion Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result.
Kh Leong - One of the best experts on this subject based on the ideXlab platform.
-
Central Serous Retinopathy complicating systemic lupus erythematosus: a case series
Clinical & experimental ophthalmology, 2000Co-Authors: Cgyw Khng, Ey Yap, Kg Au‐eong, Tock Han Lim, Kh LeongAbstract:Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with widespread manifestations including the eye. Central Serous Retinopathy (CSR) has been associated as a complicating event in SLE, although it is uncommon. We present a case series of four female Chinese SLE patients who developed CSR during the course of their systemic disease. All four presented clinically with typical CSR. Angiographic findings did not show evidence of choroidal ischaemia or delayed choroidal filling. Resolution of the Serous retinal detachment occurred in all four patients. Recovery of vision was seen in three patients. The clinical outcome was similar to that occurring in the usual male population. Central Serous Retinopathy as a manifestation of SLE may be caused by various factors. These include SLE-associated choroidopathy, systemic hypertension, renal disease, retinal pigment epithelial dysfunction and glucocorticoid therapy.
M D De Smet - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Central Serous Retinopathy with en face optical coherence tomography
The British journal of ophthalmology, 2005Co-Authors: M. E. J. Van Velthoven, F. D. Verbraak, Patricia Garcia, Reinier O. Schlingemann, Richard B. Rosen, M D De SmetAbstract:Background: The diagnosis of idiopathic Central Serous Retinopathy (CSR) is usually based on biomicroscopy and fluorescein angiography (FA). The optical coherence tomography (OCT) ophthalmoscope produces en face OCT scans (OCT C-scans) and provides additional information not readily available by conventional imaging techniques. The authors describe the characteristic features observed in patients with a clinical diagnosis of CSR using the OCT ophthalmoscope. Methods: 38 eyes with a clinical diagnosis of CSR, seen at the Academic Medical Centre (Amsterdam, Netherlands) and the New York Eye and Ear Infirmary (New York, USA) between August 2002 and March 2004, were evaluated with standard digital FA and scanned with the OCT ophthalmoscope. Results: Nine of 38 eyes had no Serous neurosensory detachment (inactive CSR) when scanned with the OCT ophthalmoscope. Characteristics for active CSR (n = 29) were large neurosensory detachment (23/29), subretinal hyper-reflective deposits (20/29), and pigment epithelial detachment (15/29). One third of the patients, either active or inactive, had multiple small pigment epithelial detachments located both within and outside the neurosensory detachment. Conclusion: The OCT ophthalmoscope provides complementary morphological information on patients with CSR. The presence of more diffuse retinal pigment epithelium (RPE) changes lends further support to the concept that CSR is a diffuse rather than localised RPE anomaly.